VEGFA and age-related macular degeneration: Furthermore, a meta-analysis of randomized trials on ranibizumab for AMD treatment identified a stronger relationship of systemic vascular adverse events and intravitreal administration of VEGF inhibitors in case of more intensive treatment schedule (Ueta et al., 2014).